FilingReader Intelligence

King-Friend subsidiary receives FDA approval; buyback remains stalled

June 9, 2025 at 09:43 PM UTCBy FilingReader AI

Nanjing King-Friend Biochemical Pharmaceutical (SSE:603707) announced that its subsidiary, Jianjin Pharmaceutical, has received U.S. FDA approval for its Hydralazine Hydrochloride Injection (20 mg/mL single-dose vial). The approval, under ANDA number 217501, covers the treatment of severe essential hypertension when oral administration is not feasible or rapid blood pressure reduction is required. Nanjing King-Friend noted that seven other companies already market similar Hydralazine Hydrochloride Injection products in the U.S., including Adrastea Pharma LLC and Hikma Pharmaceuticals USA Inc. The company has invested approximately CNY 1,105.97 million in the product’s research and development.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Nanjing King-Friend Biochemical Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →